A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma

Wirth, 2013, History of gene therapy, Gene, 525, 162, 10.1016/j.gene.2013.03.137

Flemming, 2012, Regulatory watch: pioneering gene therapy on brink of approval, Nat. Rev. Drug Discov., 11, 664, 10.1038/nrd3835

Melchiorri, 2013, Regulatory evaluation of Glybera in Europe — two committees, one mission, Nat. Rev. Drug Discov., 12, 719, 10.1038/nrd3835-c1

Chow, 1999, Rising incidence of renal cell cancer in the United States, JAMA, 281, 1628, 10.1001/jama.281.17.1628

Chow, 2010, Epidemiology and risk factors for kidney cancer, Nat. Rev. Urol., 7, 245, 10.1038/nrurol.2010.46

Li, 2014, Kidney cancer incidence and mortality among American Indians and Alaska natives in the United States, 1990–2009, Am. J. Public Health, 104, S396, 10.2105/AJPH.2013.301616

Vogelzang, 1998, Kidney cancer, Lancet, 352, 1691, 10.1016/S0140-6736(98)01041-1

Kibria, 2013, The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells, Biomaterials, 34, 5617, 10.1016/j.biomaterials.2013.03.094

Soto-Vega, 2009, P-glycoprotein activity in renal clear cell carcinoma, Urol. Oncol., 27, 363, 10.1016/j.urolonc.2008.01.011

Janowitz, 2013, Adjuvant therapy in renal cell carcinoma — past, present, and future, Semin. Oncol., 40, 482, 10.1053/j.seminoncol.2013.05.004

McDermott, 2013, Immune therapy for kidney cancer: a second dawn?, Semin. Oncol., 40, 492, 10.1053/j.seminoncol.2013.05.008

Molina, 2013, Systemic treatment options for untreated patients with metastatic clear cell renal cancer, Semin. Oncol., 40, 436, 10.1053/j.seminoncol.2013.05.013

Randall, 2010, Bevacizumab toxicities and their management in ovarian cancer, Gynecol. Oncol., 117, 497, 10.1016/j.ygyno.2010.02.021

Ginn, 2013, Gene therapy clinical trials worldwide to 2012 — an update, J. Gene Med., 15, 65, 10.1002/jgm.2698

Felgner, 1987, Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. U. S. A., 84, 7413, 10.1073/pnas.84.21.7413

Mislick, 1996, Evidence for the role of proteoglycans in cation-mediated gene transfer, Proc. Natl. Acad. Sci. U. S. A., 93, 12349, 10.1073/pnas.93.22.12349

Varga, 2005, Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes, Gene Ther., 12, 1023, 10.1038/sj.gt.3302495

Hama, 2007, Quantitative and mechanism-based investigation of post-nuclear delivery events between adenovirus and lipoplex, Nucleic Acids Res., 35, 1533, 10.1093/nar/gkl1165

Hama, 2006, Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems, Mol. Ther., 13, 786, 10.1016/j.ymthe.2005.10.007

Kircheis, 2001, Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application, Gene Ther., 8, 28, 10.1038/sj.gt.3301351

Sakurai, 2001, Effects of erythrocytes and serum proteins on lung accumulation of lipoplexes containing cholesterol or DOPE as a helper lipid in the single-pass rat lung perfusion system, Eur. J. Pharm. Biopharm., 52, 165, 10.1016/S0939-6411(01)00165-5

Nomoto, 2011, In situ quantitative monitoring of polyplexes and polyplex micelles in the blood circulation using intravital real-time confocal laser scanning microscopy, J. Control. Release, 151, 104, 10.1016/j.jconrel.2011.02.011

Ambegia, 2005, Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression, Biochim. Biophys. Acta, 1669, 155, 10.1016/j.bbamem.2005.02.001

Jeffs, 2005, A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA, Pharm. Res., 22, 362, 10.1007/s11095-004-1873-z

Tam, 2000, Stabilized plasmid-lipid particles for systemic gene therapy, Gene Ther., 7, 1867, 10.1038/sj.gt.3301308

Heyes, 2007, Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA, Mol. Ther., 15, 713, 10.1038/sj.mt.6300101

Jayaraman, 2012, Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, Angew. Chem. Int. Ed. Engl., 51, 8529, 10.1002/anie.201203263

Judge, 2005, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, Nat. Biotechnol., 23, 457, 10.1038/nbt1081

Maier, 2013, Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics, Mol. Ther., 21, 1570, 10.1038/mt.2013.124

Sakurai, 2011, Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA, Biomaterials, 32, 5733, 10.1016/j.biomaterials.2011.04.047

Sakurai, 2013, Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system, Mol. Ther., 21, 1195, 10.1038/mt.2013.57

Akita, 2013, A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA, Adv. Healthc. Mater., 2, 1120, 10.1002/adhm.201200431

Ukawa, 2014, Neutralized nanoparticle composed of SS-cleavable and pH-activated lipid-like material as a long-lasting and liver-specific gene delivery system, Adv. Healthc. Mater., 3, 1222, 10.1002/adhm.201300629

Tanaka, 2014, Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-Scaffold for nuclear targeting of plasmid DNA, Biomaterials, 35, 1755, 10.1016/j.biomaterials.2013.11.016

Shibuya, 2013, Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases, J. Biochem., 153, 13, 10.1093/jb/mvs136

Akita, 2013, A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles, Biomaterials, 34, 8979, 10.1016/j.biomaterials.2013.08.003

Hatakeyama, 2007, Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid, Gene Ther., 14, 68, 10.1038/sj.gt.3302843

Hatakeyama, 2004, Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo, Int. J. Pharm., 281, 25, 10.1016/j.ijpharm.2004.05.025

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387

Hyde, 2008, CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression, Nat. Biotechnol., 26, 549, 10.1038/nbt1399

Yan, 2005, The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse, Biochem. Biophys. Res. Commun., 328, 57, 10.1016/j.bbrc.2004.12.137

Akinc, 2010, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol. Ther., 18, 1357, 10.1038/mt.2010.85

Ishida, 2002, Liposome clearance, Biosci. Rep., 22, 197, 10.1023/A:1020134521778

Ogris, 1999, PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery, Gene Ther., 6, 595, 10.1038/sj.gt.3300900

Hatakeyama, 2011, A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response, Mol. Ther., 19, 1487, 10.1038/mt.2011.24

Koshkaryev, 2013, Immunoconjugates and long circulating systems: origins, current state of the art and future directions, Adv. Drug Deliv. Rev., 65, 24, 10.1016/j.addr.2012.08.009

Sato, 2012, A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo, J. Control. Release, 163, 267, 10.1016/j.jconrel.2012.09.009

Hatakeyama, 2011, A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma, Adv. Drug Deliv. Rev., 63, 152, 10.1016/j.addr.2010.09.001

Hatakeyama, 2013, The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors, Biol. Pharm. Bull., 36, 892, 10.1248/bpb.b13-00059

Mishra, 2004, PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles, Eur. J. Cell Biol., 83, 97, 10.1078/0171-9335-00363

Remaut, 2007, Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides, J. Control. Release, 117, 256, 10.1016/j.jconrel.2006.10.029

Hatakeyama, 2011, Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid, Biomaterials, 32, 4306, 10.1016/j.biomaterials.2011.02.045

De Oliveira, 2000, Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice, Life Sci., 67, 1625, 10.1016/S0024-3205(00)00745-1

Mold, 1989, Effect of membrane phospholipids on activation of the alternative complement pathway, J. Immunol., 143, 1663, 10.4049/jimmunol.143.5.1663

Goelden, 2005, Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma, Urol. Int., 75, 269, 10.1159/000087807

Pfoertner, 2005, Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma, Tumour Biol., 26, 313, 10.1159/000089262

Hama, 2014, Nanoparticles consisting of tocopheryl succinate are a novel drug-delivery system with multifaceted antitumor activity, Biol. Pharm. Bull., 37, 196, 10.1248/bpb.b13-00848

Hama, 2012, Development of a novel drug delivery system consisting of an antitumor agent tocopheryl succinate, J. Control. Release, 161, 843, 10.1016/j.jconrel.2012.05.031

Fukuzawa, 2004, Enhancement of nitric oxide and superoxide generations by alpha-tocopheryl succinate and its apoptotic and anticancer effects, Biochemistry (Mosc), 69, 50, 10.1023/B:BIRY.0000016351.77553.74